CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

DNL151Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D010300 Parkinsonian NIH 0.58

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Subjects With Parkinson's Disease

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DNL151 in subjects with Parkinson's disease.

NCT04056689 Parkinson's Disease Drug: DNL151 Drug: Placebo
MeSH:Parkinson Disease

Primary Outcomes

Measure: Number of Subjects with Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

Time: Randomization to Day 42

Measure: Number of Subjects with laboratory test abnormalities

Time: Randomization to Day 42

Measure: Number of Subjects with vital sign abnormalities

Time: Randomization to Day 42

Measure: Number of Subjects with electrocardiogram (ECG) abnormalities

Time: Randomization to Day 42

Measure: Number of Subjects with clinically significant neurological examination abnormalities

Time: Randomization to Day 42

Secondary Outcomes

Measure: Pharmacokinetic measure of maximum observed plasma concentration (Cmax) of DNL151

Time: Randomization to Day 28

Measure: Pharmacokinetic measure of time to reach maximum observed plasma concentration (Tmax) of DNL151

Time: Randomization to Day 28

Measure: Pharmacokinetic measure of trough plasma observed concentration (Ctrough) of DNL151

Time: Randomization to Day 28

Measure: Pharmacokinetic measure of area under the plasma drug concentration-time curve (AUC) of DNL151

Time: Randomization to Day 28

Measure: Pharmacokinetic measure of CSF concentrations of DNL151

Time: Randomization to Day 28

Measure: Pharmacodynamic measure of pS935 in whole blood

Time: Randomization to Day 28

Measure: Pharmacodynamic measure of pRab10 in PBMCs

Time: Randomization to Day 28

No related HPO nodes (Using clinical trials)